SEC Form 4 · accession 0001209191-18-039169
Oncotelic Therapeutics, Inc. · OTLC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Matthew M Loar
Officer — Chief Financial Officer
Period of report
Jun 20, 2018
Accepted (ET)
Jun 22, 2018 · 4:12 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000908259
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F1,F2 | $0.22 | Jun 20, 2018 | A | 250,000 | A | — | Jun 20, 2028 | Common Stock | 250,000 | 250,000 | D |
| Employee Stock Option (Right to Buy)F3,F2 | $0.22 | Jun 20, 2018 | A | 500,000 | A | — | Jun 20, 2028 | Common Stock | 500,000 | 500,000 | D |
Explanation of responses
- F1Mr. Loar was awarded options to purchase Mateon Therapeutics, Inc. common stock, $0.01 par value per share (the "2017 Plan Options"), pursuant to the Mateon Therapeutics, Inc. 2017 Equity Incentive Plan in connection with his service as Chief Financial Officer.
- F2The Options will vest in twelve equal monthly installments beginning one month after the date of grant.
- F3Mr. Loar was awarded options to purchase Mateon Therapeutics, Inc. common stock, $0.01 par value per share (the "2015 Plan Options" and, collectively with the 2017 Plan Options, the "Options"), pursuant to the Amended and Restated Mateon Therapeutics, Inc. 2015 Equity Incentive Plan in connection with his service as Chief Financial Officer.